Overexpression of hepatoma-derived growth factor in melanocytes does not lead to oncogenic transformation

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Sedlmaier, Angela ^a   Wernert, Nicolas ^b   Gallitzendörfer, Rainer ^a   Abouzied, Mekky M ^c   Gieselmann, Volkmar ^a   Franken, Sebastian ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY HOSPITAL BONN   (Germany)

^c Minia University   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; HEPATOMA-DERIVED GROWTH FACTOR; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER RISK; CONTROLLED STUDY; EPIDERMOID CYST; GENE OVEREXPRESSION; HAIR FOLLICLE; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INK4A GENE; MALIGNANT TRANSFORMATION; MELANOCYTE; MELANOMA; MOUSE; MOUSE STRAIN; NONHUMAN; RADIATION EXPOSURE; SUPPRESSOR GENE; TRANSGENIC MOUSE; ULTRAVIOLET RADIATION; WESTERN BLOTTING; WILD TYPE; ANIMAL; ANTIBODY SPECIFICITY; C57BL MOUSE; CELL TRANSFORMATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE ORDER; GENE TARGETING; GENETICS; GENOTYPE; METABOLISM; PATHOLOGY; SKIN;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE ORDER; GENE TARGETING; GENOTYPE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MELANOCYTES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; ORGAN SPECIFICITY; SKIN;

EID: 80054687126     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-457     Document Type: Article

References (54)

1. Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, Yamamoto H, Kishimoto T. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem 1994, 269(40):25143-25149.
2. Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, Yamamoto H, Sato J, Kishimoto S. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta 1989, 183(3):273-284. 10.1016/0009-8981(89)90361-6, 2553304.
3. Abouzied MM, El-tahir HM, Prenner L, Haberlein H, Gieselmann V, Franken S. Hepatoma-derived Growth Factor:Significance of Amino Acid Residues 81-100 in Cell Surface Interaction and Proliferative Activity. J Biol Chem 2005, 280(12):10945-10954. 10.1074/jbc.M414652200, 15655245.
4. Everett AD, Bushweller J. Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets 2003, 4(5):367-371. 10.2174/1389450033490975, 12816346.
5. Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem 2001, 276(40):37564-37568. 10.1074/jbc.M105109200, 11481329.
6. Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M, Kuroda T, Ito H, Yoshizaki K, Nakamura H. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem 2002, 277(12):10315-10322. 10.1074/jbc.M111122200, 11751870.
7. Abouzied MM, Baader SL, Dietz F, Kappler J, Gieselmann V, Franken S. Expression patterns and different subcellular localization of the growth factors HDGF (hepatoma-derived growth factor) and HRP-3 (HDGF-related protein-3) suggest functions in addition to their mitogenic activity. Biochem J 2004, 378(Pt 1):169-176. 1223924, 14572309.
8. Enomoto H, Yoshida K, Kishima Y, Kinoshita T, Yamamoto M, Everett AD, Miyajima A, Nakamura H. Hepatoma-derived growth factor is highly expressed in developing liver and promotes fetal hepatocyte proliferation. Hepatology 2002, 36(6):1519-1527.
9. Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest 1998, 102(6):1208-1219. 10.1172/JCI785, 509104, 9739055.
10. Nakamura H, Yoshida K, Ikegame K, Kishima Y, Uyama H, Enomoto H. Antibodies against hepatoma-derived growth factor and mucosal repair in ulcerative colitis. J Gastroenterol 2002, (37 Suppl 14):8-14.
11. Nakamura H, Yoshida K, Kishima Y, Enomoto H, Uyama H, Kuroda T, Okuda Y, Hirotani T, Ito H, Kawase I. Circulating auto-antibody against hepatoma-derived growth factor (HDGF) in patients with ulcerative colitis. Hepatogastroenterology 2004, 51(56):470-475.
12. Narron JV, Stoops TD, Barringhaus K, Matsumura M, Everett AD. Hepatoma-derived growth factor is expressed after vascular injury in the rat and stimulates smooth muscle cell migration. Pediatr Res 2006, 59(6):778-783. 10.1203/01.pdr.0000219299.24435.4f, 16641209.
13. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. J Leukoc Biol 2007, 81(1):1-5.
14. Zong WX, Thompson CB. Necrotic death as a cell fate. Genes Dev 2006, 20(1):1-15. 10.1101/gad.1376506, 16391229.
15. Gallitzendoerfer R, Abouzied MM, Hartmann D, Dobrowolski R, Gieselmann V, Franken S. Hepatoma-derived growth factor (HDGF) is dispensable for normal mouse development. Dev Dyn 2008, 237(7):1875-1885. 10.1002/dvdy.21589, 18570251.
16. Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, Khuri FR, Mao L. Expression of Hepatoma-Derived Growth Factor Is a Strong Prognostic Predictor for Patients With Early-Stage Non-Small-Cell Lung Cancer. J Clin Oncol 2004, 22(16):3230-3237. 10.1200/JCO.2004.02.080, 15310766.
17. Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, Changchien CS, Lee CM, Chuang JH, Tai MH. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer 2003, 98(7):1444-1456. 10.1002/cncr.11653, 14508832.
18. Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, Ito H, Hoshida Y, Aozasa K, Nagano H, Sakon M, Kawase I, Monden M, Nakamura H. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol 2006, 13(2):159-167. 10.1245/ASO.2006.11.035, 16411141.
19. Lepourcelet M, Tou L, Cai L, Sawada J-I, Lazar AJF, Glickman JN, Williamson JA, Everett AD, Redston M, Fox EA, Nakatani Y, Shivdasani RA. Insights into developmental mechanisms and cancers in the mammalian intestine derived from serial analysis of gene expression and study of the hepatoma-derived growth factor (HDGF). Development 2005, 132(2):415-427. 10.1242/dev.01579, 15604097.
20. Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, Doki Y, Yoshida K, Aozasa K, Nakamura H, Monden M. Expression of Hepatoma-Derived Growth Factor Is Correlated with Lymph Node Metastasis and Prognosis of Gastric Carcinoma. Clin Cancer Res 2006, 12(1):117-122. 10.1158/1078-0432.CCR-05-1347, 16397032.
21. Yamamoto S, Makuuchi H, Shimada H, Chino O, Nishi T, Kise Y, Kenmochi T, Hara T. Clinical analysis of reflux esophagitis following esophagectomy with gastric tube reconstruction. J Gastroenterol 2007, 42(5):342-345. 10.1007/s00535-007-2011-6, 17530357.
22. Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, Enomoto H, Okuda Y, Sakon M, Aozasa K, Kawase I, Hayashi N, Monden M. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res 2006, 12(20 Pt 1):6043-6048.
23. Bernard K, Litman E, Fitzpatrick JL, Shellman YG, Argast G, Polvinen K, Everett AD, Fukasawa K, Norris DA, Ahn NG, Resing KA. Functional proteomic analysis of melanoma progression. Cancer Res 2003, 63(20):6716-6725.
24. Hu TH, Lin JW, Chen HH, Liu LF, Chuah SK, Tai MH. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum 2009, 52(2):319-326. 10.1007/DCR.0b013e31819d1666, 19279430.
25. Ren H, Chu Z, Mao L. Antibodies targeting hepatoma-derived growth factor as a novel strategy in treating lung cancer. Mol Cancer Ther 2009, 8(5):1106-1112. 10.1158/1535-7163.MCT-08-0779, 2933960, 19435872.
26. Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of Hepatoma-Derived Growth Factor Inhibits Anchorage-Independent Growth and Invasion of Non-Small Cell Lung Cancer Cells. Cancer Res 2006, 66(1):18-23. 10.1158/0008-5472.CAN-04-3905, 16397209.
27. Machuy N, Thiede B, Rajalingam K, Dimmler C, Thieck O, Meyer TF, Rudel T. A Global Approach Combining Proteome Analysis and Phenotypic Screening with RNA Interference Yields Novel Apoptosis Regulators. Mol Cell Proteomics 2005, 4(1):44-55.
28. Shen XY, Zacal N, Singh G, Rainbow AJ. Alterations in mitochondrial and apoptosis-regulating gene expression in photodynamic therapy-resistant variants of HT29 colon carcinoma cells. Photochem Photobiol 2005, 81(2):306-313. 10.1562/2004-07-22-RA-242.1, 15560738.
29. Serrano M, Lee H, Chin L, Cordon-Cardo C, Beach D, DePinho RA. Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85(1):27-37. 10.1016/S0092-8674(00)81079-X, 8620534.
30. Bancroft J, H C. Manual of histological techniques and their diagnostic application. Churchill Livingstone 1994,
31. Fewou SN, Bussow H, Schaeren-Wiemers N, Vanier MT, Macklin WB, Gieselmann V, Eckhardt M. Reversal of non-hydroxy:alpha-hydroxy galactosylceramide ratio and unstable myelin in transgenic mice overexpressing UDP-galactose:ceramide galactosyltransferase. J Neurochem 2005, 94(2):469-481. 10.1111/j.1471-4159.2005.03221.x, 15998297.
32. Harlow E, Lane D. Antibodies: a laboratory manual. 1988, Cold Spring Habor, NY: Cold Spring Habor Laboratory Press.
33. Beermann F, Schmid E, Ganss R, Schutz G, Ruppert S. Molecular characterization of the mouse tyrosinase gene: pigment cell-specific expression in transgenic mice. Pigment Cell Res 1992, 5(5 Pt 2):295-299.
34. Tief K, Hahne M, Schmidt A, Beermann F. Tyrosinase, the key enzyme in melanin synthesis, is expressed in murine brain. Eur J Biochem 1996, 241(1):12-16. 10.1111/j.1432-1033.1996.0012t.x, 8898882.
35. Tief K, Schmidt A, Aguzzi A, Beermann F. Tyrosinase is a new marker for cell populations in the mouse neural tube. Dev Dyn 1996, 205(4):445-456. 10.1002/(SICI)1097-0177(199604)205:4<445::AID-AJA8>3.0.CO;2-I, 8901055.
36. Tief K, Schmidt A, Beermann F. Regulation of the tyrosinase promoter in transgenic mice: expression of a tyrosinase-lacZ fusion gene in embryonic and adult brain. Pigment Cell Res 1997, 10(3):153-157. 10.1111/j.1600-0749.1997.tb00477.x, 9266602.
37. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner JW, DePinho RA. Cooperative effects of INK4a and ras in melanoma susceptibility in vivo. Genes Dev 1997, 11(21):2822-2834. 10.1101/gad.11.21.2822, 316663, 9353252.
38. Kelsall SR, Mintz B. Metastatic cutaneous melanoma promoted by ultraviolet radiation in mice with transgene-initiated low melanoma susceptibility. Cancer Res 1998, 58(18):4061-4065.
39. Noonan FP, Recio JA, Takayama H, Duray P, Anver MR, Rush WL, De Fabo EC, Merlino G. Neonatal sunburn and melanoma in mice. Nature 2001, 413(6853):271-272. 10.1038/35095108, 11565020.
40. Thomas J, Liu T, Cotter MA, Florell SR, Robinette K, Hanks AN, Grossman D. Melanocyte expression of survivin promotes development and metastasis of UV-induced melanoma in HGF-transgenic mice. Cancer Res 2007, 67(11):5172-5178. 10.1158/0008-5472.CAN-06-3669, 2292453, 17545596.
41. Grote W, Lund OE. Observations on pathogenesis of an unusual intraspinal epidermoid. Dtsch Z Nervenheilkd 1957, 176(1):48-54.
42. Sandoval R, Urbina F. Pigmented follicular cyst. Br J Dermatol 1994, 131(1):130-131. 10.1111/j.1365-2133.1994.tb08470.x, 8043405.
43. Shet T, Desai S. Pigmented epidermal cysts. Am J Dermatopathol 2001, 23(5):477-481. 10.1097/00000372-200110000-00015, 11801783.
44. Lippens S, Hoste E, Vandenabeele P, Agostinis P, Declercq W. Cell death in the skin. Apoptosis 2009, 14(4):549-569. 10.1007/s10495-009-0324-z, 19221876.
45. Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest 2000, 105(5):567-575. 10.1172/JCI7497, 289171, 10712428.
46. Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol 2004, 286(6):L1194-1201. 10.1152/ajplung.00427.2003, 14751852.
47. Enomoto H, Nakamura H, Komatsu-Kanatani N, Liu Y, Yoshida K, Okuda Y, Yamamoto T, Liu W, Nishiguchi S. Partial blockage of hepatocyte maturation in hepatoma-derived growth factor transgenic mice. World J Hepatol 2009, 1(1):98-102. 10.4254/wjh.v1.i1.98, 2999260, 21160971.
48. Hoelbl A, Schuster C, Kovacic B, Zhu B, Wickre M, Hoelzl MA, Fajmann S, Grebien F, Warsch W, Stengl G, Hennighausen L, Poli V, Beug H, Moriggl R, Sexl V. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med 2010, 2(3):98-110. 10.1002/emmm.201000062, 2906698, 20201032.
49. Fulda S. Tumor resistance to apoptosis. Int J Cancer 2009, 124(3):511-515. 10.1002/ijc.24064, 19003982.
50. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 2009, 136(5):823-837. 10.1016/j.cell.2009.02.024, 2894612, 19269363.
51. Solimini NL, Luo J, Elledge SJ. Non-oncogene addiction and the stress phenotype of cancer cells. Cell 2007, 130(6):986-988. 10.1016/j.cell.2007.09.007, 17889643.
52. Liao F, Dong W, Fan L. Apoptosis of human colorectal carcinoma cells is induced by blocking hepatoma-derived growth factor. Med Oncol 2009, 27(4):1219-1226.
53. Tsang TY, Tang WY, Tsang WP, Co NN, Kong SK, Kwok TT. Downregulation of hepatoma-derived growth factor activates the Bad-mediated apoptotic pathway in human cancer cells. Apoptosis 2008, 13(9):1135-1147. 10.1007/s10495-008-0241-6, 18651222.
54. Tsang TY, Tang WY, Tsang WP, Co NN, Kong SK, Kwok TT. Mechanistic study on growth suppression and apoptosis induction by targeting hepatoma-derived growth factor in human hepatocellular carcinoma HepG2 cells. Cell Physiol Biochem 2009, 24(3-4):253-262. 10.1159/000233250, 19710540.